Business Context and Reporting Period
MannKind Corporation is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diabetes and cancer. The reporting period covers the fiscal year ended December 31, 2006. The company is in the development stage with no commercial products currently on the market. Its lead investigational product, the Technosphere Insulin System, is in Phase 3 clinical trials globally. The company also initiated Phase 1 clinical trials for a cancer immunotherapy candidate (MKC1106-PP) in January 2007.
Key Financial Metrics
| Metric | 2006 | 2005 |
|---|---|---|
| Revenue | $0.1 million | $0 |
| Net Loss | $(230.5) million | $(114.3) million |
| Net Loss Per Share (Basic & Diluted) | $(4.52) | $(2.87) |
| Research & Development Expenses | $191.8 million | $95.3 million |
| General & Administrative Expenses | $42.0 million | $22.8 million |
| Cash, Cash Equivalents & Marketable Securities | $436.5 million | $145.6 million |
| Working Capital | $404.6 million | $128.5 million |
| Senior Convertible Notes (3.75% due 2013) | $111.3 million (net proceeds) | $0 |
| Accumulated Deficit | $(787.8) million | $(557.3) million |
Material Changes vs. Prior Period
- Capital Raising: In December 2006, the company closed a public offering of common stock raising approximately $384.7 million in net proceeds and issued $115.0 million in Senior Convertible Notes, raising approximately $111.3 million in net proceeds. This significantly increased cash reserves from $145.6 million in 2005 to $436.5 million in 2006.
- Expense Growth: Operating expenses increased significantly, driven by the expansion of Phase 3 clinical trials for the Technosphere Insulin System. R&D expenses more than doubled to $191.8 million, and G&A expenses increased 84% to $42.0 million.
- Accounting Changes: The adoption of SFAS No. 123R (Share-Based Payment) on January 1, 2006, resulted in a significant increase in stock-based compensation expense, totaling $14.7 million for the year, compared to a benefit of $(1.7) million in 2005.
- Debt Repayment: The company repaid a $70.0 million loan from its principal stockholder in December 2006 using proceeds from the new financing.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects to continue incurring operating losses for the foreseeable future. Based on current capital resources, the company believes it can fund operations into the first quarter of 2008. However, additional financing will be required to complete development and commercialization.
- Clinical Progress: The company is conducting pivotal Phase 3 trials for Technosphere Insulin. A two-year safety study enrollment was completed in September 2006. The company anticipates needing two years of controlled safety data before filing a New Drug Application (NDA).
- Risks:
- Regulatory Approval: The FDA regulates the Technosphere Insulin System as a combination product (drug and device), which may lengthen the review process.
- Competition: Pfizer's Exubera was approved in 2006. Other competitors include Eli Lilly's AIR system and Novo Nordisk's AERx system.
- Intellectual Property: The company faces potential patent infringement claims from third parties regarding pulmonary insulin delivery and DNA-based vaccines.
- Litigation: A lawsuit filed by the former Chief Medical Officer (Dr. Cheatham) alleging wrongful termination is scheduled for trial in April 2007. The company believes the allegations are without merit.
- Contingencies: The company has a $150 million loan arrangement with its principal stockholder available if cash balances fall below projected requirements, though no amounts were outstanding as of year-end.
Investor Verification Checklist
- Cash Runway: Verify the company's ability to fund operations through Q1 2008 given the high burn rate ($189.8 million used in operations in 2006).
- Clinical Trial Milestones: Monitor the completion dates and results of the pivotal Phase 3 efficacy trials (Studies 009 and 102) and the two-year safety study (Study 030).
- Regulatory Strategy: Confirm the FDA's final determination on the combination product review process and any specific requirements for pulmonary safety data.
- Intellectual Property Status: Review the status of patent applications and any ongoing or potential infringement litigation regarding inhaled insulin technology.
- Litigation Outcome: Track the resolution of the Cheatham lawsuit scheduled for April 2007 and any potential financial or reputational impact.
- Stock-Based Compensation: Assess the impact of SFAS 123R on future earnings, as stock-based compensation is a significant non-cash expense.